Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCRx T Cells in Advanced Gastric/Gastroesophageal Junction Cancer
NCT05447234Phase 1Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2023
- Primary completion
- Mar 2026
- Modality
- TCR-Engineered T Cells
01
Overview
Phase 1, open-label, single-arm trial of Tcrx T cell in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: tumor volume at 2 years and Overall Survival at 2 years. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
Tcrx T cell
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05447234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05447234.